Mon, 12 Oct 2020 00:00:00 BST
A University of Glasgow-led national centre for research into inflammatory arthritis is proud to announce it has awarded 12 PhDs in its first round of funding, creating a new cadre of young scientists trained in pathogenesis research to fight arthritis
Fri, 03 Jul 2020 09:01:00 BST
The University of Glasgow, in collaboration with the NHS and Scottish tech companies, will lead a £3.37m project to transform bowel cancer screening in the UK by developing a precision diagnostic tool that uses artificial intelligence to predict which patients will develop future polyps and tumours.
Fri, 26 Jun 2020 07:07:00 BST
The University of Glasgow has been awarded £38m to create the Precision Medicine Living Lab – an internationally leading project focused on translating cutting-edge science and innovation into a real world clinical setting.
- Tackling the challenge of multimorbidity in chronic kidney disease; Medical Research Council, £194k (2020-23).
- Effects of Covid-19 pandemic on diabetes risks and outcomes in UK; Diabetes UK, £83k (2020-22).
- Accurate, Reliable and Optimized functional MAgnetic resonance imaging at unprecedented field strength; European Commission, £355k (2020-25).
- Stratified Medicine Scotland Innovation Centre (Phase 2); Scottish Funding Council, £7.5M (2019-24).
- TNF antagonism and brain monocyte recruitment in sickness behaviour in rheumatoid arthritis; Medical Research Council, £1.2M (2019-22).
- Scientists develop new 'precision medicine' approach to treating damaged DNA in pancreatic cancer
- Breakthrough research breathes hope into a new treatment for asthma
- Glasgow team will transform bowel cancer screening into a precision medicine tool using
- Joint cell discovery offers new hope for people with rehumatoid arthritis
- UofG awarded £38M to deliver game-changing precision medicine project
- Scottish scientists play a key role in new 'comprehensive' map of cancer genomes
- Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis. Nature Medicine (2020).
- Pan-cancer analysis of whole genomes. Nature Medicine (2020).
- Pathophysiological regulation of lung function by the free fatty acid receptor FFA4. Science Translational Medicine. (2020).
- Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. British Journal of Cancer (2019)
- Glycated Hemoglobin, Prediabetes, and the Links to Cardiovascular Disease: Data From UK Biobank. Diabetes Care (2019).
Scotland has a high incidence of chronic disease. There are rising numbers of people living with multiple long-term disorders, impacting on quality of life and increasing costs to the NHS.
The University’s Clinical Innovation Zone at the Queen Elizabeth University Hospital (QEUH) campus is now Scotland’s focal point for the implementation of precision medicine. The Zone is home to the Precision Medicine Scotland Innovation Centre (PMS-IC, formerly the Stratified Medicine Scotland Innovation Centre).
Precision Medicine is an approach which enables doctors and researchers to identify and develop treatments that are effective for particular groups of patients, using advanced genomic, imaging and information technologies. Precision medicine will ensure that the right patient gets the right treatment at the right time, and will provide safer and more cost-effective treatments.
Partnering with NHS Greater Glasgow & Clyde, the University of Glasgow has driven Scotland’s vision in precision medicine, including the development of over £80m infrastructure to support precision medicine clinical trials at the QEUH. Our £32m Imaging Centre of Excellence (ICE) includes Scotland’s only 7 Tesla MRI scanner, an ultra-high resolution scanner, which is the first of its kind fully integrated within a clinical site in the UK. ICE will drive the development of imaging technology to understand and benefit diseases such as stroke, brain tumours and multiple sclerosis.
The University is one of Innovate UK’s Precision Medicine Centres of Excellence and our ambition is to be a global centre of excellence for chronic disease, precision medicine and imaging. Capitalising on our investment in infrastructure and biomedical researchers to drive international research excellence and patient benefits, and deliver economic benefit for Scotland and the UK.